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The prevalence of HFpEF in studies has
been reported as 40-71%.1 This variation
reflects both the current challenges in
accurately diagnosing HFpEF and that
different LVEF cutoffs (varying from 
> 40% to > 55%) have been used. 
In 2007, the average number of
patients on a practice list in England was
6,487 which would equate to around 
50 patients with HFpEF per practice.
However, the true overall prevalence of
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ability of the heart to cope with the
metabolic needs of the body, resulting 
in breathlessness, fatigue and fluid
retention. It is a progressive disease
characterised by high rates of
hospitalisation. The National Heart
Failure Audit in England and Wales in
2012/2013 reported that 5% of all
emergency hospitalisations were related
to heart failure, with 11% inpatient
mortality and 26% of those discharged
dead within the follow-up period.3
At present HF affects nearly one
million people in the UK.3,4 Studies
suggest that approximately half these
patients have normal, or near normal,
left ventricular ejection fraction (LVEF)
and are classified as heart failure with
preserved ejection fraction (HFpEF).5
» estimated to be higher, with eachpractice likely to have approximately200 patients with HFpEF.6
PATHOPHYSIOLOGY
The exact pathophysiology of HFpEF
remains uncertain although increased
left ventricle passive stiffness is
consistently reported.7,8 Patients often
have overlapping comorbidities and it
has only recently been convincingly
demonstrated that HFpEF represents
more than the sum of all its
comorbidities and is a condition in its
own right.9
HFpEF is likely to be caused by:
diastolic dysfunction, impaired systolic
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muscle metabolism and perfusion,
pulmonary hypertension and renal
insufficiency.8 
HFpEF was initially referred to as
diastolic HF as opposed to systolic HF
that corresponded with HFrEF (heart
failure with reduced ejection fraction).
However, diastolic dysfunction has been
shown not to be unique to HFpEF.
Furthermore, newer imaging techniques
have confirmed that systolic function in
HFpEF patients is not completely
normal, with reduced long axis function
and extensive but subtle changes on
exercise. HFpEF is the accepted name,
although preserved implies that the left
ventricular ejection fraction was known
previously and is unchanged, which is
not always the case.10
RISK FACTORS 
Large epidemiological studies have
found that HFpEF patients are likely to
be older women with a history of
hypertension.5,11,12Other cardiovascular
risk factors, such as diabetes mellitus,
atrial fibrillation and coronary artery
disease are prevalent in the HFpEF
population, see figure 1, pxx. Non-
cardiovascular comorbidities, renal
impairment, chronic lung disease, liver
disease, hypothyroidism and anaemia,
consistent with an elderly population
have also been reported.13
PRESENTATION
Clinical symptoms and signs in HFpEF
are often nonspecific although the
primary symptoms of HF are
breathlessness, fatigue and fluid
retention. 
Patients often find their exercise
tolerance is limited by fatigue and
breathlessness. Fluid overload can result
in weight gain, peripheral oedema, or
swelling of the ankles and legs, as well as
abdominal congestion, resulting in
impaired absorption and contributing to
renal dysfunction. 
Depression is common in heart failure,
with a prevalence of 20-40%.14 Patients
with heart failure and depression have
been found to have increased morbidity
and mortality with impaired quality of
life, when compared with heart failure
patients without depression.15,16
The New York Heart Association
(NYHA) functional classification
provides an easy way to classify patients
depending on their physical limitations,
see table 1, above.17 Criticisms of the
classification system focus on difficulties
defining the difference between slight
and marked limitation18 with low
reproducibility values between
clinicians.19 However, the NYHA
classification system provides a rapid
assessment of exercise capacity that is
easy to communicate and has been well
documented to predict prognosis.20, 21 
Table 1







Patients have cardiac disease but without limitation of physical
activity. Ordinary physical activity does not cause undue fatigue,
palpitation, dyspnoea 
Patients have cardiac disease resulting in slight limitation of physical
activity. Comfortable at rest. Ordinary physical activity results in
fatigue, palpitation, dyspnoea 
Patients have cardiac disease resulting in marked limitation of physical
activity. Comfortable at rest. Less than ordinary activity causes fatigue,
palpitation, or dyspnoea  
Patients have cardiac disease resulting in inability to carry out any
physical activity without discomfort. Symptoms of heart failure at rest.




Despite significant advances in medical
imaging, the cornerstone in the
assessment of HF remains a thorough
medical history and physical
examination, see figure 2, opposite.
There is still no single diagnostic test 
for HFpEF. 
The medical history needs to include
previous cardiac disease such as
coronary artery disease and atrial
fibrillation, as well as previous episodes
of hospitalisation. Other cardiovascular
risk factors and family history should be
documented.
The duration of symptoms is relevant
as are the extent of symptoms such as
chest pain, breathlessness and exercise
limitation. It is useful to classify patients
according to the NYHA functional
assessment. Rapid weight gain is
suggestive of fluid overload, whereas
anorexia, weight loss and early satiety
suggest cardiac cachexia that is
associated with an adverse prognosis.22
The physical examination needs to
include the patient’s BMI and weight,
heart rate and rhythm, lying and
standing blood pressure and
auscultation to rule out valvular disease
and pulmonary congestion. 
Estimating the jugular venous
pressure and the presence of peripheral
oedema allows assessment of the
patient’s volume status. Cool extremities
indicate poor cardiac output and
perfusion. Hepatomegaly and ascites
both indicate fluid overload. 
CONFIRMING DIAGNOSIS
Recent guidelines have been published
to improve the diagnosis of HFpEF, see
table 2, above.1,23 Echocardiography is
clearly critical in the diagnosis of HFpEF,
but not all GPs have access to this and
most have to refer patients to their local
cardiology departments. 
Before referral an ECG can be
performed to check for heart rate and
rhythm, as well as any suggestion of
previous ischaemic disease, left
ventricular hypertrophy or atrial
enlargement. Blood tests for full blood
count, serum electrolytes including
magnesium and calcium, renal function,
thyroid function, glucose, liver function,
fasting lipid profile and NT-proBNP, see
box 1, below, can all add important
information to the early assessment of 
a patient with suspected HFpEF. 
Patients with heart failure should be
referred to heart failure nurses and have
follow-up with local cardiology services,
as these have both been shown to
reduce mortality.3
Once the patient has been referred to
cardiology, it is likely that further
specialist investigations will be
undertaken, such as cardiac magnetic
resonance imaging, coronary
angiography, computer tomography
coronary angiography,  exercise testing
and lung function tests. 
LONG-TERM OUTCOMES 
Studies suggest that the mortality rate in
HFpEF patients is substantial ranging
from 10 to 30%, with higher rates in
epidemiological studies than clinical
trials.24 Mortality rates are clearly higher
than controls matched for age and
comorbidities25 and may be as high as
mortality rates in HFrEF.5,11 In clinical trials,
sudden death and HF death are the
leading causes of cardiovascular death.26
Survival has improved in HFrEF over the
past 10 to 20 years although no change
has been observed for HFpEF patients.
MANAGEMENT 
Given the uncertainty in diagnoses and
pathophysiology it is not surprising that
there have been no evidence-based
HFpEF therapies beyond treatment
directed at comorbidities and diuretics
for fluid overload.8 Several large-scale
trials have demonstrated neutral results
although there were no universal entry
criteria and so different populations
have been studied. Recent heart failure
guidelines have concluded that ‘no
treatment has yet been shown
convincingly to reduce mortality or
morbidity in patients with HFpEF’. 
The recommendations include
managing breathlessness and fluid
overload with diuretics, managing heart
rate control and treating myocardial
ischaemia and hypertension.23
Drug therapy
Loop diuretics and thiazides are
effective for the rapid relief of 
Table 2
Diagnostic criteria in HFpEF
European Society of Cardiology, 201223
1 Symptoms and signs typical of heart
failure
2 Normal, or only mildly reduced LVEF
3Relevant structural heart disease 
left ventricular hypertrophy, 
atrial enlargement
4 ±diastolic dysfunction
American College of Cardiology/
American Heart Association, 2013 1
1 Symptoms and signs typical of heart
failure
2 Normal LVEF




BNP or its amino-terminal cleavage equivalent (NT-proBNP) is generated by
cardiomyocytes in the context of numerous triggers, most notably myocardial
stretch. Assays for both BNP and NT-proBNP are increasingly used to establish
the presence and severity of HF. Either can be used in patient care settings as long
as their respective absolute values are not used interchangeably.1 The value
of natriuretic peptide testing is particularly significant when the aetiology of
dyspnoea is unclear, and if BNP is normal it is unlikely that the patient has 
heart failure. 
Patients with HFpEF have lower levels of BNP than HFrEF patients. However, for a
given BNP level, the prognosis (risk of all-cause mortality and HF hospitalisation)
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symptoms and may improve quality of
life, although do not reduce morbidity or
mortality.27 There is some evidence that
thiazide diuretics may reduce morbidity
and mortality in older hypertensive
patients.28,29 There is no such evidence
for loop diuretics. Identifying and
treating depression is important in these
patients. 
CONCLUSION
The prevalence of HF is expected to
increase by 25% by 203030 and
approximately half of all HF patients
have HFpEF. 
HFpEF represents a collection of
different conditions and current imaging
and physiological research is seeking to
understand this better and improve
characterisation.
Symptoms and signs of heart failure
are central to the diagnosis of HFpEF.
Currently no treatments have
convincingly been shown to reduce
mortality or morbidity in these patients
with comparable outcome data to HFrEF. 
Improved characterisation of HFpEF
will enable future trials to define
inclusion criteria, ensuring that similar
patients are being studied. 
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Heart failure affects nearly one million people in the UK, 
half of these patients have normal, or near normal left
ventricular ejection fraction and are classified as heart
failure with preserved ejection fraction (HFpEF).
Newer imaging techniques have confirmed that systolic 
function in HFpEF patients is not completely normal, with
reduced long axis function and extensive but subtle
changes on exercise. Patients are likely to be older women
with a history of hypertension. Other cardiovascular risk
factors, such as diabetes mellitus, atrial fibrillation and
coronary artery disease are prevalent in the HFpEF
population.
Clinical symptoms and signs in HFpEF are often 
nonspecific although the primary symptoms are
breathlessness, fatigue and fluid retention. Fluid overload
can result in weight gain, peripheral oedema, or swelling
of the ankles and legs, as well as abdominal congestion.
Depression is common in heart failure, with a 
prevalence of 20-40%. Patients with heart failure and
depression have been found to have increased morbidity
and mortality with impaired quality of life, when compared
with heart failure patients without depression. Identifying
and treating depression is important in these patients.
There is still no single diagnostic test for HFpEF 
and the cornerstone in the assessment remains a thorough
medical history and physical examination. The duration and
extent of the symptoms are relevant and it is useful to
classify patients according to the NYHA functional
assessment. Rapid weight gain is suggestive of fluid
overload, whereas anorexia, weight loss and early satiety
suggest cardiac cachexia that is associated with an adverse
prognosis.
Physical examination should include the patient’s BMI 
and weight, heart rate and rhythm, lying and standing
blood pressure and auscultation to rule out valvular disease
and pulmonary congestion. Estimating the jugular venous
pressure and the presence of peripheral oedema allows
assessment of the patient’s volume status.
Patients with heart failure should be referred to heart 
failure nurses and have follow-up with local cardiology
services. as these have both been shown to reduce
mortality. Breathlessness and fluid overload should be
managed with diuretics, heart rate controlled and
myocardial ischaemia and hypertension treated. Loop
diuretics and thiazides are effective for the rapid relief of
symptoms and may improve quality of life, although they
do not reduce morbidity or mortality. There is some
evidence that thiazide diuretics may reduce morbidity and




the rapid relief 
of symptoms’
